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4SP Biofilm group with Streptococcus sanguinis, Aggregatibacter
actinomycetemcomitans, Candida albicans, and
Fusobacterium nucleatum
4SP+LGG Biofilm group with S. sanguinis, A. actinomycetemcomitans,
C. albicans, F. nucleatum, and LGG
5SP Biofilm group with S. sanguinis, A. actinomycetemcomitans,
C. albicans, F. nucleatum, and S. mutans
5SP+LGG Biofilm group with S. sanguinis, A. actinomycetemcomitans,
C. albicans, F. nucleatum, S. mutans, and LGG
Aa Biofilm group with A. actinomycetemcomitans
ATCC American type culture collection
BHI Brain Heart Infusion
BOP Bleeding on probing
Ca Biofilm group with C. albicans
CFU Colony-forming unit
CLSM Confocal laser scanning microscopy
EIR Effective inhibition ratio
FISH Fluorescence in situ hybridization
Fn Biofilm group with F. nucleatum
GI Gingival index
HA Hydroxyapatite
LGG Lactobacillus rhamnosus GG or LGG®
MMP-3 Matrix metalloproteinase-3
MPO Myeloperoxidase
MRS De Man, Rogosa, and Sharpe medium
MS Mutans streptococci
O/N Overnight
OD Optical density
PD Pocket/probing depth
PI Plaque index
PS Physiological saline
Sm Biofilm group with S. mutans
SRP Scaling and root planing
Ss Biofilm group with S. sanguinis
6ABSTRACT
In the following series of in vitro studies, we aimed to investigate the interactions
between probiotic lactobacilli and opportunistic oral pathogen species under
various conditions. Our study hypothesis was that probiotics integrate into oral
biofilms, interact with species in the biofilms, and thus alter their pathogenic
potential, which further reduces the risk for some common infectious oral diseases.
Investigations on probiotic properties in the presence of oral pathogens in vitro
could facilitate and expand our understanding of inherent modes of probiotic
activity.
First, we evaluated the inhibitory activity of six commercial probiotic lactobacilli
against Candida albicans and non-albicans Candida with an agar-overlay method.
The inhibitory activity of probiotic lactobacilli against C. albicans was strain-
dependent and varied according to pH and carbohydrate source. Lactobacillus
rhamnosus GG (LGG) and C. albicans were the species we selected for the sub-
studies that followed, because LGG showed the strongest inhibitory activity, and C.
albicans was the most susceptible yeast.
Second, we assessed the potential risk for lactobacilli on dental hard tissues by
investigating the pH of the spent culture medium of lactobacilli in planktonic
cultures and in single-species biofilms, as well as when co-cultured with other
microbes. In five-species biofilms (5SP) in the presence of LGG, LGG was able to
grow well with lactose or sucrose as its only carbohydrate source. LGG did not
significantly reduce the pH when cultivated with the other five species of oral
pathogens in biofilms, nor did the carbohydrate source affect the pH values.
Third, we investigated the growth of (opportunistic) oral pathogens in the presence
or absence of LGG in dual- and multi-species biofilms under five carbohydrate
conditions. Probiotic LGG promoted the growth of Streptococcus mutans and of S.
sanguinis compared to their growth without LGG; LGG suppressed, however, the
growth of C. albicans; and C. albicans and S. mutans significantly promoted the
growth of LGG. LGG showed no impact on the growth of the pathogens in group
75SP+LGG (including all of the pathogens tested), but LGG was able to reduce the
growth ratio of S. sanguinis in four-species biofilms+LGG (including all of the tested
pathogens except S. mutans).
Further evaluated was also the susceptibility of biofilm species to commercial
mouthwashes. LGG neither enhanced nor weakened the mouthwash antimicrobial
effects on the pathogens. Their recovery after mouthwash rinsing was not
influenced by the residual LGG.
In conclusion, LGG could inhibit the growth of C. albicans; however, C. albicans
promoted the growth of LGG. Differing from the traditional understanding, LGG
growing with multi-species biofilms could survive and grow well under conditions in
which lactose or sucrose was the only carbohydrate source. Probiotic LGG and
pathogenic streptococci could benefit each other when co-cultured in dual-species
biofilms, but this phenomenon did not occur in multi-species biofilms. The
probiotics showed no influence on the antimicrobial effect of mouthwashes.
81 INTRODUCTION
The term “probiotic”, first mentioned in 1965, has developed to mean “live
microorganisms that, when administered in adequate amounts, confer a health
benefit on the host” [Hill et al., 2014]. Probiotics are often added to ordinary
fermented food, such as yoghurt, bread, or kimchi. They can also be found in
drugstores as food supplements in various forms such as tablets, drops, and
capsules.
Growing evidence has shown that consuming probiotics may alleviate some of the
symptoms of oral conditions caused by imbalances in oral microbial homeostasis.
For instance, intake of probiotics has reduced the count of salivary mutans
streptococci (MS), of periodontal pathogens, and of Candida yeasts, and has
reduced the plaque index, gingival bleeding on probing, periodontal pocket depth,
and gingival inflammation [Ince et al., 2015; Ghasemi et al., 2017; Miyazima et al.,
2017].
The underlying mechanisms of the benefits are still unclear, however. Probiotics
have shown inhibitory effects on (opportunistic) pathogens, which is also one of the
most important criteria for screening new promising probiotics. Many in vitro
studies have repeatedly and conclusively shown that probiotic lactobacilli inhibit
the growth of MS and periodontal pathogens, but only recent studies have
investigated the growth inhibition by probiotics against Candida in laboratory
conditions, especially in biofilm models.
Multi-species biofilms are natural living formats of microorganisms, showing far
stronger resistance to inhibitory substances than shown by planktonic cells [Orazi
and O'Toole, 2019]. Few studies have, however, tested the growth of oral
(opportunistic) pathogens in the presence of probiotics in dual-species biofilms or
in multi-species biofilms.
In addition, the safety of probiotics is of major concern. Probiotic lactobacilli
generate acids, a process that may pose potentially harmful effects on dental hard
tissues. Some studies found that probiotic lactobacilli have led to mineral loss in
9tooth enamel [Schwendicke et al., 2014], but some have disputed this finding
[Pham et al., 2011].
Most probiotic-pathogen studies focus more on the growth of pathogens, because
the amount of probiotics administered is adjustable based on need. The potential
growth of probiotics is essential to determine, however, prior to deciding upon
their optimal amounts in preparations and the format of their delivery.
In daily life, individuals use more than one method to prevent biofilm-related oral
diseases. Conflicts may appear in the combination of chemical and biological
methods. Few studies have investigated, for instance, the influence of mouthwash
use on probiotic efficacy, and the effect of probiotics on the efficacy of
mouthwashes.
This thesis therefore aimed to investigate how probiotic lactobacilli and oral
(opportunistic) pathogens grow in experimental biofilms and to assess their mutual
interactions under differing conditions. The hypothesis was that probiotics
integrate into oral biofilms, interact with species in the biofilms, and alter its
pathogenic potential, all of which further reduce the growth of biofilms and thus
reduce the burden of common infectious oral diseases.
10
2 REVIEW OF THE LITERATURE
2.1 Oral microbes and microbial biofilms
2.1.1 Oral microbes
The expanded Human Oral Microbiome Database has claimed that 771 microbial
species, including cultivated and uncultivated phylotypes, are detectable in the
human aerodigestive tract (www.ehomd.org) [Chen et al., 2010]. The diversity of
microbes inhabiting the oral cavity is mainly affected by age, food intake, individual
genetics, and immune defenses, and also affected by intake of antimicrobial agents.
Furthermore, because of the various niches of the oral cavity, the composition of
microbes differs between those on the surface of the teeth, in the gingival crevices,
on the tongue, cheeks, lips, and the hard and soft palates. Via the inflamed
periodontal pockets, these microbes can enter the bloodstream and reach distant
parts of the body.
2.1.2 Biofilms
In nature, microbes live as planktonic cells in liquid and air and as biofilms on
surfaces. Biofilms were first described in a report by the Dutch merchant Antonie
van Leeuwenhoek: “the number of these animalcules in the scurf of a man’s teeth
are so many that I believe they exceed the number of men in a kingdom.” In the last
two decades, research on biofilms became a serious scientific endeavor in
microbiology. Now we know that a biofilm is a structured consortium of microbes
embedded in a self-produced polymer matrix mainly consisting of polysaccharides,
proteins, nucleic acids, and lipids [Flemming and Wingender, 2010; Hoiby et al.,
2010].
Without any oral hygiene practice, the biofilm starts forming in the oral cavity
within four hours after each meal [Palmer et al., 2003]. The first colonizers, usually
streptococci, attach to the saliva pellicle on the surface of the tooth or mucosal
epithelium or on both, and then come the next colonizers, and gradually they form
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the organized multispecies community that interacts within the microbial members
and with the environment [Marsh, 2005; Verma et al., 2018].
2.2 Biofilm-associated oral diseases
When the balance of the microbial ecology in the oral cavity is perturbed for a
certain period, biofilm-related poly-microbial diseases may occur, for example
dental caries, periodontal diseases, and yeast infections.
2.2.1 Dental caries
The World Health Organization (WHO) has claimed that dental caries is the most
common non-communicable disease worldwide and is the leading pathology in the
permanent teeth (2.3 billion people affected) [WHO., 2017]. Dental caries is a
multifactorial outcome of the complex interactions among the caries-associated
microbes, a long-term frequent supply of fermentable carbohydrates, plus
susceptible tooth surfaces without proper oral hygiene. Recent molecular-
approach-based studies have clearly shown that dental caries is a poly-microbial-
associated disease [Simon-Soro and Mira, 2015]. When the balance of
demineralization and remineralization shifts towards a net mineral loss, acid-
producing microbes, for example, MS, non-MS, and Actinomyces, greatly contribute
to the development of caries. S. mutans, especially, is considered to play a major
etiological role in the caries progression, due to its ability to adhere to the tooth
surface, by producing sticky extracellular polysaccharides from sucrose, and by
fermenting sucrose and other sugars to acids, which cause mineral loss from the
tooth enamel [Hamada and Slade, 1980].
2.2.2 Periodontal diseases
Periodontal diseases, with a high prevalence affecting up to 90% of the world’s
population, are clinically manifested as inflammation of the soft tissues around the
teeth [Pihlstrom et al., 2005]. Clinical observations have indicated that periodontal
diseases are associated with accumulated dental biofilms adjacent to the gingival
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crevices and in periodontal pockets. Furthermore, individuals with gingivitis and
periodontitis may be at higher risks for the chronic inflammatory and systemic
diseases, for example cardiovascular diseases, stroke, Alzheimer’s disease, and
diabetes mellitus [Söder et al., 2015; Beukers et al., 2017; Pritchard et al., 2017;
Graziani et al., 2018]. Generally, the most routinely isolated bacteria are
Porphyromonas gingivalis, Tannerella forsythensis, Treponema denticola,
Aggregatibacter actinomycetemcomitans, and Fusobacterium nucleatum. A great
number of previously unknown pathogens are being identified with new molecular
and sequencing techniques [Hiranmayi et al., 2017].
2.2.3 Yeast infections
An oral yeast infection known as thrush or candidiasis, is common and is caused by
the genus Candida. Many of the Candida strains live as commensal strains in the
host, but in immunocompromised individuals, their virulence and pathogenic
properties may be enhanced, leading to clinical manifestations like chronic mucosal
infections, and even to life-threatening systemic diseases. These diseases are most
frequently induced by Candida albicans, but also by non-albicans Candida strains,
for example C. glabrata, C. krusei, and C. tropicalis [Hani et al., 2015].
2.3 Oral hygiene
To prevent biofilm-associated oral diseases by reduction or control of the
accumulated dental biofilms, the basic practice for individuals is appropriate oral
self-care [Kumar et al., 2016; Sicca et al., 2016; Lertpimonchai et al., 2017]. Home-
based oral hygiene can include mechanical cleaning such as by toothbrushing, and
also including chemical cleaning, such as with antiseptic mouthwashes.
2.3.1 Mechanical cleaning
Mechanical cleaning normally includes cleaning of the teeth and interdental spaces,
oral mucosa, and tongue with a brush, dental floss, and a moist cotton swab.
Mechanical cleaning is considered to be the most reliable procedure for plaque
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removal, which is essential for the prevention of oral diseases. However, dental
biofilms are nearly impossible to remove completely, such as those in gingival
margins, fissures, buccal pits, and in the posterior interproximal areas, where oral
diseases mostly develop [Sheiham and Sabbah, 2010; Jongsma et al., 2015].
2.3.2 Chemical cleaning
Chemical cleaning refers to rinsing with mouthwashes to clean the teeth and oral
mucosa relying on the antimicrobial and anti-biofilm-forming properties of these
products. Mouthwash rinse usually serves as a support to mechanical cleaning. It
can also be the only oral care for patients who are unable to brush their teeth, and
who have, for example, recently undergone surgery, or for individuals with motor
or cognitive impairments [Tartaglia et al., 2017]. Of the antiseptic components,
chlorhexidine is the gold standard, which is recommended only for the short-term
use because of its potential adverse effects, like tooth discoloration [Zanatta et al.,
2010].
2.4 Probiotics
2.4.1 History
In 1905, Stamen Grigorov, a Bulgarian physician, identified a species of
Lactobacillus in the starter culture of a fermented Bulgarian dairy product. Based on
this finding, in the following year the later Nobel laureate Élie Metchnikoff
published a book Prolongation of life: Optimistic studies, which postulated that the
cause underlying the longer life of Bulgarian peasants was the yogurt that they
consumed, containing health-beneficial bacteria [Ozen and Dinleyici, 2015]. Henry
Tissier, in 1900, was the first scientist to conceive the idea that friendly bacteria
could be useful in treating intestinal diseases [Farré-Maduell and Casals-Pascual,
2019]. Today, those microorganisms are indeed called “probiotics”.
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2.4.2 Definition
The meaning of “probiotic” is “fit for life, lively.” The term was defined as “growth
promoting factors produced by microorganisms” according to Lilly and Stillwell
[1965]. After many decades of evolution, probiotics now are defined as “live
microorganisms that, when administered in adequate amounts, confer a health
benefit on the host” [Hill et al., 2014]. The hosts can be humans, animals [Yang et
al., 2017], or plants [Kim and Anderson, 2018]. Probiotic strains that have
demonstrated human-health benefits mainly belong to the genera of Lactobacillus,
Streptococcus, Enterococcus, Lactococcus, Pediococcus, Leuconostoc,
Bifidobacterium, Bacillus, Escherichia coli, and Saccharomyces [Fijan, 2014].
2.4.3 Probiotics and general health
The human body harbors more microbial cells than human cells [Sender et al.,
2016]. Microbial cells reside in such areas as the gastrointestinal tract, skin, hair,
external auditory canal, nostrils, vagina, and penis. [Blum, 2017]. A balanced
microbial ecosystem is essential to physiology, immunity, and mental health. Once
the balance shifts towards an unhealthier situation, dysbiosis symptoms, or
diseases, or both may appear. Antimicrobial therapy has prolonged the human life
span, beginning with the detection of penicillin. However, nowadays, one of the
greatest threats to global life is antibiotic resistance. Alternative prevention
methods and treatments are thus urgently needed. Probiotics have drawn the
attention of researchers and medical professionals because of usually showing no
adverse effects.
Knowledge of probiotic effects on microbial diseases is accumulating. What has
been clinically demonstrated is that probiotic intervention proves effective for the
prevention and treatment of certain gut diseases such as infectious diarrhea,
antibiotic-associated diarrhea, inflammatory bowel diseases, irritable bowel
syndrome, Helicobacter pylori infection, and lactose intolerance [Sanchez et al.,
2017]. Probiotics have shown promise in improving the vaginal environment by
maintaining its normal lactobacilli count [Vladareanu et al., 2018]. They have also
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helped to prevent allergies [Fiocchi et al., 2015], to improve acne vulgaris and
atopic dermatitis [Jung et al., 2013; Fabbrocini et al., 2016; Prakoeswa et al., 2017;
Zhao et al., 2018], to ease postpartum depression and anxiety [Slykerman et al.,
2017], and to offer other benefits. These benefits are believed to be strain specific.
Zmora et al. [2018] suggest that probiotic products should be tailored to each
individual’s specific health needs, rather than prescribing one product to all.
Knowledge of the exact mechanisms of probiotic action is, however, limited.
Locally, it may include a competition with pathogens for adhesion sites and
nutrients, or include inhibition of the pathogens’ growth by secretion of
bacteriocins and similar products, therefore modulating the composition and
activity of the indigenous microorganisms. Furthermore, probiotics’ local beneficial
effects may enhance epithelial barrier function, modulate the immune system and
its systemic metabolic responses by signaling via the central nervous system, and
also may regulate human general health and physiology [Sommer and Backhed,
2013; Lebeer et al., 2018].
2.4.4 Probiotics and oral health
Probiotics and dental caries
A reduced count of salivary MS is regarded as a major indicator of reduced risk for
caries in clinical trials (Table 1). Short- and long-term intakes of probiotics have
shown the potential to prevent caries and to reduce caries development. The
positive effects of probiotics could be as efficient as chewing xylitol-containing gum
[Ghasemi et al., 2017]. MS-inhibiting results have also appeared from in vitro
studies [Conrads et al., 2019; Nunpan et al., 2019].
The mechanism of the beneficial effects may be a shifting of the microbial ecology
in the oral cavity towards a more beneficial state of equilibrium producing fewer
organic acids. One mechanism of action causing inhibition of growth, of biofilm
formation, or of the virulence properties of MS, –or any combination of these–
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involves bioactive substances released by probiotics [Rossoni et al., 2018b; Wasfi et
al., 2018].
Probiotic interventions have, however, also failed to result in any significant change
in plaque and salivary MS counts [Cildir et al., 2012; Keller et al., 2012; Marttinen et
al., 2012; Villavicencio et al., 2018]. One suggestion is that probiotic intervention to
prevent caries may prove more effective in children at high risk for caries
[Rodriguez et al., 2016; Villavicencio et al., 2018]. Moreover, who differ in their
eating habits, ethnicities, ages, or locations may harbor greatly differing oral
microorganisms, and may respond differently to any specific probiotic
administration [Percival et al., 1991; Sampaio-Maia and Monteiro-Silva, 2014;
Gupta et al., 2017; Lira-Junior et al., 2018]. This indicates that probiotic
administration should indeed be tailored to each individual.
Table 1. Clinical effects of commercial probiotic products/strains on dental caries
and related conditions.
Strain(s) Delivery
format
Test duration/
Tested
population
Outcome Reference
Lactobacillus
rhamnosus SP1
Milk 10 months/2-3
yrs with high risk
for caries
Reduced caries
development
[Rodrigue
z et al.,
2016]
L. rhamnosus
CGMCC 1.3724,
and
Bifidobacteriu
m longum
ATCC BAA-999
Milk 9 months/3-4 yrs No significant reduction
in Streptococcus mutans
counts, no caries-
preventive effect
[Villavicen
cio et al.,
2018]
LGG Milk 7 months/1-6 yrs Reduced dental caries
and lower MS counts;
effects particularly clear
in children aged 3 or 4
years
[Nase et
al., 2001]
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Strain(s) Delivery
format
Test duration/
Tested
population
Outcome Reference
L. rhamnosus
LB21
Milk 15 months/58-84
yrs
Root caries index reversal
occurred, and electric
resistance measurement
values increased,
indicating
remineralization. Both
effects enhanced with
fluoride.
No significant alteration
in microbial counts
[Petersso
n et al.,
2011]
L. paracasei
SD1
Milk
powder
4 weeks/18-25
yrs
Reduction in salivary MS
counts
[Teanpais
an and
Piwat,
2014]
L. rhamnosus
LB21
Milk with
fluoride
21 months/1-5
yrs
Milk-containing
probiotics reduced caries
development
[Stecksen-
Blicks et
al., 2009]
L. acidophilus
ATCC 4356 and
B. bifidum
ATCC 2951
Yogurt 3 weeks/19-27
yrs female
Reduction in salivary MS
counts, as effective as
chewing gum with xylitol
[Ghasemi
et al.,
2017]
L. reuteri DSM
17938 and L.
reuteri ATCC
PTA 5289
Drop 25 days/4-12 yrs
operated
children with
cleft lip or palate
No significant changes in
salivary MS and
lactobacilli counts
[Cildir et
al., 2012]
L. reuteri ATCC
55730
Freeze-
dried
powder
in oil
drops
(mixed
refined
coconut
oil and
peanut
oil, 3:1)
1 + 12 months/
expectant
mothers during
final month of
gestation and
newborn babies
from families
with allergic-
disease history
Reduced caries
prevalence at age 9
years, but no significant
changes in MS and
lactobacilli counts in
saliva and plaque, or in
secretory IgA
[Stensson
et al.,
2014]
B. lactis BB-12
and L.
acidophilus La-
5
Ice-
cream
10 days/12-14
yrs with no
detectable
clinical caries
Reduction in salivary MS
counts
[Singh et
al., 2011]
L. paracasei
F19
Cereal 9 months/
4-month-old
full-term infants
No effects on prevention
of caries at ages 3, 6, 9
years, no effect on
salivary MS or lactobacilli
at age 9
[Hasslof et
al., 2013]
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Strain(s) Delivery
format
Test duration/
Tested
population
Outcome Reference
LGG Tablet 2
weeks/25.3±2.4
yrs
No significant changes in
plaque MS counts and no
significant alteration of
acidogenicity of supra-
gingival plaque. No
significant change in
plaque lactobacilli
[Marttine
n et al.,
2012]
L. reuteri
SD2112 and L.
reuteri PTA
5289
Tablet 2
weeks/25.3±2.4
yrs
No significant changes in
plaque MS counts and no
significant alteration of
acidogenicity of supra-
gingival plaque.
Significant increase in
plaque lactobacilli
[Marttine
n et al.,
2012]
B. animalis
subsp. lactis
BB-12
Tablet until 2 yrs old/
1-2-month-old
babies
No effects on caries
occurrence at age 4 in a
low-caries population
[Taipale et
al., 2013]
S. uberis KJ2,
S. oralis KJ3,
and S. rattus
JH145
Chewing
tablet
1 year/2-3 yrs Reduced risk for early
childhood caries
development
[Hedayati-
Hajikand
et al.,
2015]
L. reuteri DSM
17938 and L.
reuteri ATCC
PTA 5289
Lozenge 6 weeks/19-35
yrs with
moderate or high
counts of salivary
MS
No effect on regrowth of
MS after full-mouth
disinfection with
chlorhexidine
[Keller et
al., 2012]
L. paracasei
ADP-1
Tooth-
paste
Brushing for 30 s
and swishing for
30 s/10-12 yrs
with no caries
Reduced MS mono-
species biofilms. Effect
short, when exposed to
sucrose
[Srinivasa
n et al.,
2017]
MS: mutans streptococci; yrs: years; s: seconds.
Probiotics and periodontal diseases
Tlaskalova-Hogenova et al. [2004] have indicated that probiotics can prevent or
treat chronic diseases because the regulation of microbial composition affects the
development of mucosal and systemic immunity. Beneficial effects of probiotics on
periodontal diseases have been confirmed in a number of clinical studies (Table 2),
but the mechanisms remain poorly understood.
Until now, the most extensively studied probiotic genus for periodontal health has
been Lactobacillus, specifically the species L. reuteri. Almost all the published
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clinical studies using L. reuteri (mainly Prodentis® lozenges, BioGaia, Lund, Sweden)
showed positive effects on periodontal disease parameters. For example, a reduced
gingival index was evident [Ince et al., 2015; Tekce et al., 2015], as well as reduced
pocket depth [Teughels et al., 2013; Vicario et al., 2013; Ince et al., 2015; Tekce et
al., 2015], reduced counts of inflammatory pathogens [Iniesta et al., 2012; Teughels
et al., 2013], and improved attachment gain [Teughels et al., 2013]. The positive
effects may be due to reuterin, a bacteriocin produced by L. reuteri. Reuterin has
the ability to induce oxidative stress in cells, thereby showing bacteriostatic and
bactericidal activities against a wide range of pathogenic microorganisms [Schaefer
et al., 2010].
Promising results have also emerged from probiotic studies with L. plantarum L-137
[Iwasaki et al., 2016], L. brevis CD2 [Shah et al., 2017], and L. salivarius WB21
[Shimauchi et al., 2008]. Heat-killed L. plantarum L-137 has proven to be a potent
inducer of interleukin-12 [Murosaki et al., 1998], which leads to a T-helper-1-type
immune response through induction of interferon-β and interferon-γ [Murosaki et
al., 1999; Arimori et al., 2012]. Riccia et al. [2007] suggested that the beneficial
effect of L. brevis may result from arginine deiminase, which prevents nitric oxide
generation. The administration, in sachets, of L. rhamnosus SP1, the effect of which
was believed to be similar to the effect of azithromycin, did not, however,
demonstrate better effects than did mechanical scaling and root planing alone
[Morales et al., 2016; 2018]. The reasons are unclear, but delivery format, dosage,
and frequency of administration may also influence the intervention outcomes.
During the past six years, researchers’ interest has increased in studying another
commonly used probiotic genera, namely Bifidobacterium. Bifidobacterium alone
[Kuru et al., 2017; Invernici et al., 2018] and mixed with lactobacilli [Toiviainen et
al., 2015; Montero et al., 2017; Yousuf et al., 2017; Alanzi et al., 2018; Becirovic et
al., 2018] underwent various investigation of their ability to reduce the risk for
periodontal disease. All tests resulted in positive effects. In one in vitro study,
Jasberg et al. [2016] demonstrated that the Bifidobacterium animalis subsp. lactis
BB-12 showed an inhibitory effect on the growth of Porphyromonas gingivalis.
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However, administration of a combination of three species of Streptococcus, as
investigated by Laleman et al. [2015] did not achieve the expected benefits
concerning periodontal disease, based on clinical and microbiological parameters,
although some streptococci seemed to reduce the inflammatory response induced
by pathogenic microorganisms in vitro and in vivo [Zhang and Rudney, 2011; Kaci et
al., 2014]. Alkaya et al. [2017] and Tsubura et al. [2009] have also reported
inconsistent results from Bacillus intervention. In a rat model with ligature-induced
periodontitis, probiotic Bacillus reduced attachment loss, alveolar bone loss, and
tissue breakdown [Messora et al., 2013; Foureaux Rde et al., 2014].  Such
inconsistent results may be the result of the probiotic concentration, delivery
format, or parameter measurements.
Table 2. Clinical effects of commercial probiotic products/strains on periodontal
diseases and related conditions.
Strain(s) Delivery
format
Test duration/
Tested
population
Outcome Reference
L. casei Shirota Milk 8 weeks/mean
age 24.4±1.9
Decreased elastase
activity and MMP-3
amount. Increased MPO
activity
[Staab et
al., 2009]
Bifidobacterium
animalis subsp.
lactis BB-12, L.
acidophilus La-5
and LGG
Milk 3 weeks/dental
students
Reduction of periodontal
pathogens
[Becirovic
et al.,
2018]
B. animalis
subsp. lactis DN-
173010
Yogurt 28 days/16-26
yrs
Reduced plaque
accumulation and
gingival inflammation
[Kuru et
al., 2017]
L. reuteri ATCC
55730
Freeze-
dried
powder in
oil drops
(mixed
refined
coconut
oil and
peanut
oil, 3:1)
1 + 12 months/
expectant
mothers during
final month of
gestation and
newborn
babies from
families with
allergic-disease
history
Reduced gingival
bleeding index at age 9,
no significant change in
PI
[Stensson
et al.,
2014]
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Strain(s) Delivery
format
Test duration/
Tested
population
Outcome Reference
L. reuteri ATCC
55730 and L.
reuteri ATCC
PTA 5289
(Prodentis®)
Tablet 30 days/³18
yrs
Decreased PI, BOP, and
PD
[Vicario et
al., 2013]
L. reuteri
DSM17938 and
L. reuteri ATCC
PTA 5289
(Prodentis®)
Tablet 8 weeks/20-24
yrs
Reduced counts of
periodontal pathogens
[Iniesta et
al., 2012]
L. salivarius
WB21
Tablet 8 weeks/32-61
yrs
Reduced PI, PD, and
salivary lactoferrin
[Shimauch
i et al.,
2008]
L. plantarum
CECT 7481, L.
brevis CECT
7480, and
Pediococcus
acidilactici CECT
8683
Tablet 6 weeks/18-55
yrs
Reduction in number of
sites with severe
inflammation
[Montero
et al.,
2017]
S. oralis KJ3, S.
uberis KJ2, and
S. rattus JH145
Tablet 12 weeks/37-
58 yrs with SRP
No significant differences
in clinical nor
microbiological
parameters, but
decreased number of
sites with plaque, and
decreased counts of
Prevotella intermedia
[Laleman
et al.,
2015]
L. brevis CD2 Lozenge 14 days/14-35
yrs with
aggressive
periodontitis
Reduced GI. Effect
equivalent to that of
doxycycline
[Shah et
al., 2017]
LGG and B.
lactis BB-12
Lozenge 4 weeks/13-15
yrs
Reduction in GI.
Reduction in periodontal
pathogens (saliva and
plaque A.
actinomycetemcomitans,
P. gingivalis)
[Alanzi et
al., 2018]
L. reuteri Lozenge 360 days/35-50
yrs with SRP
Decreased PI, GI, BOP,
and PD. Reduction in
inflammatory markers
[Ince et
al., 2015]
L. reuteri
DSM17938 and
L. reuteri ATCC
PTA 5289
(Prodentis®)
Lozenge 360 days/mean
age 43±5.01,
and 41.4±8.86
with SRP
Decreased PI, GI, BOP,
and PD
[Tekce et
al., 2015]
22
Strain(s) Delivery
format
Test duration/
Tested
population
Outcome Reference
L. reuteri
DSM17938 and
L. reuteri ATCC
PTA 5289
(Prodentis®)
Lozenge 12 weeks/³35
yrs with SRP
Decreased PD, improved
attachment gain, and
reduction in periodontal
pathogens
[Teughels
et al.,
2013]
LGG and B.
animalis subsp.
lactis BB-12
Lozenge 4 weeks/mean
age 24.6±2.7,
24±3.0 yrs
Decreased PI and GI [Toiviaine
n et al.,
2015]
B. animalis
subsp. lactis
HN019
Lozenge 30 days/³30
yrs with
treatment of
SRP
Decreased PD, improved
attachment gain,
reduced counts of
periodontal pathogens,
and lower pro-
inflammatory cytokine
levels
[Invernici
et al.,
2018]
L. rhamnosus
SP1
Sachet 3 months/³35
yrs with SRP
No significant differences
in clinical and
microbiological
improvements
[Morales
et al.,
2016;
2018]
L. plantarum L-
137
Capsule
containing
heat-killed
strains
12
weeks/mean
age 66.2 yrs
Decreased PD [Iwasaki et
al., 2016]
Bacillus subtilis,
Ba. megaterium,
and Ba. pumilus
Tooth-
paste/
mouth
rinse/
toothbrus
h cleaner
8 weeks/18-31
yrs
No significant differences
in clinical parameters
[Alkaya et
al., 2017]
Ba.  subtilis E-
300
Mouth-
wash
1 month/44-62
yrs
Reduction in GI, and in
periodontal pathogens
[Tsubura
et al.,
2009]
L. acidophilus, B.
longum, B.
bifidum, and B.
lactis
Freeze-
dried
powder in
water as
mouth-
rinse
3 weeks/12-15
yrs
Decreased gingival status
and decreased plaque
accumulation
[Yousuf et
al., 2017]
Lactic acid
Bacillus
Freeze-
dried
powder in
water as
mouth-
rinse
3 weeks/12-15
yrs
Decreases in gingival
status and in plaque
accumulation
[Yousuf et
al., 2017]
MPO: myeloperoxidase; MMP-3: matrix metalloproteinase-3; PI: plaque index; GI:
gingival index; BOP: bleeding on probing; PD: pocket/probing depth; SRP: scaling
and root planing; yrs: years.
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Probiotics and yeast infections
Table 3 shows that Ahola et al. [2002] reported the first clinical study of probiotic
use against Candida. In the past decade, a number of studies agreed with this
Candida-inhibitory effect caused by probiotics administered in various delivery
formats [Hatakka et al., 2007; Dos Santos et al., 2009; Mendonca et al., 2012; Li et
al., 2014; Ishikawa et al., 2015; Kraft-Bodi et al., 2015; Miyazima et al., 2017; Lee et
al., 2019] in adults and in the elderly. Several in vitro studies also have revealed that
the growth and biofilm formation of Candida can be inhibited by probiotic cells and
their supernatants [Kheradmand et al., 2014; Matsubara et al., 2016; Ribeiro et al.,
2017; Song and Lee, 2017; Rossoni et al., 2018a; Tan et al., 2018].
The suggested mechanisms are that probiotic Lactobacillus has the potential to
reduce the hyphae formation and adhesion ability of Candida, deplete them in
nutrients, and thus lessen their pathogenic potential [Basson, 2000; Krzysciak et al.,
2017; Tan et al., 2017; de Barros et al., 2018]. In addition, the antimicrobial effects
of probiotics may possibly be modified by enhanced epithelial-barrier function
through the induction of cytokine secretion and the production of antimicrobial
substances [Bermudez-Brito et al., 2012; Mendonca et al., 2012].
However, the reductions in Candida counts were undetectable in 5- to 10-year-old
caries-active children and also were undetectable in individuals with systemic oral
lichen planus [Burton et al., 2013; Keller and Kragelund, 2018]. The reasons for the
discrepancy between studies need further clarification.
Table 3. Clinical effects of commercial probiotic products/strains on yeast infections
and related conditions.
Strain(s) Delivery
format
Test duration/
Tested population
Outcome Reference
L. casei Shirota
and B. breve
Yakult
Juice 30 days/³65 yrs
female
Reduction in
Candida and
increase in anti-
Candida IgA
[Mendonca
et al., 2012]
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Strain(s) Delivery
format
Test duration/
Tested population
Outcome Reference
L. casei Shirota
and B. breve
Yakult
Yogurt 20 days/healthy
young individuals
Reduction in
Candida and in
anti-Candida
IgA
[Dos Santos
et al., 2009]
LGG, L. rhamnosus
LC 705
Cheese 3 weeks/18-35 yrs Reduction in
yeast counts
[Ahola et
al., 2002]
LGG, L. rhamnosus
LC 705,
Propionibacterium
freudenreichiii ssp
shermanii JS
Cheese 16 weeks/70-100 yrs Reduction in
prevalence of
high salivary
Candida counts
(³ 104 CFU/mL),
reduction in
hyposalivation
[Hatakka et
al., 2007]
L. acidophilus
NCFM or L.
rhamnosus Lr-32
Cheese 8 weeks/elderly,
complete-denture
wearers
Reduction in
Candida
[Miyazima
et al., 2017]
S. salivarius M18 Lozenge 3 months/5-10 yrs
caries-active
children
No significant
reduction in
saliva Candida
counts
[Burton et
al., 2013]
B. longum, L.
bulgaricus and S.
thermophilus
Lozenge 4 weeks/18-75 yrs  Reduction in
Candida during
the treatment
of Candida-
associated
stomatitis
[Li et al.,
2014]
L. reuteri
DSM17938 and L.
reuteri ATCC PTA
5289
Lozenge 12 weeks/60-102 yrs
living in nursing
home
Reduction in
Candida in
saliva and
plaque
[Kraft-Bodi
et al., 2015]
L. reuteri
DSM17938 and L.
reuteri ATCC PTA
5289
Lozenge 16 weeks/with
systemic oral lichen
planus
No differences
in Candida
counts or in
Candida carrier
status
[Keller and
Kragelund,
2018]
L. rhamnosus
HS111, L.
acidophillus
HS101, and B.
bifidum
Lyophilized
powder
5 weeks/61.6±9.8
yrs, candidiasis-
asymptomatic,
denture wearers
Reduction in
Candida
[Ishikawa et
al., 2015]
L. rhamnosus SP1 Sachet
probiotic
with milk
12 months/³60 yrs,
Candida-associated
denture stomatitis
in the elderly
Reduction in
severity of
denture
stomatitis
[Lee et al.,
2019]
CFU: colony-forming units.
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2.4.5 Safety issues
Due to the long history of safe consumption of probiotic-containing fermented
foods, probiotics are generally recognized as safe. Despite this reassuring history,
and for quality-control reasons, the safety of probiotic administration has been
under continuous study. What must be taken into account are the health status of
consumers, the characterization of mono- and multi-strains, the vehicle and
manner of administration, and the dosage and frequency of exposure [Sanders et
al., 2010].
The genus Lactobacillus is crucial to the modern probiotic industry. Consumption of
Lactobacillus-containing dairy products is high in France, for example, where the
risk for Lactobacillus infection for over a century has been 5 cases per 50 million
residents [Bernardeau et al., 2006]. Although the pathogenesis of Lactobacillus
infection is unknown, clinical studies make clear that use of probiotic lactobacilli
has shown no adverse effects on immunologically vulnerable populations, ones
including patients with HIV [Salminen et al., 2004; Ishizaki et al., 2017; Happel et al.,
2018] and groups of premature infants [Miloh, 2015]. In Finland, the increased
consumption of probiotic food did not lead to any increase in the incidence of
Lactobacillus bacteremia in the period 1995 to 2000 [Salminen et al., 2002].
In addition, to evaluate the safety of probiotic use regarding oral health, probiotics
need to meet not only all the requirements for their general health effects, but also
they should not reduce oral pH in the presence of dietary sugars. A lowered pH
favors a shift toward an acid-tolerant and acid-producing consortium of
microorganisms, which alters the balance from remineralization toward
demineralization, hence favoring caries progression [Takahashi and Nyvad, 2011].
As a lactic acid bacterium, Lactobacillus is naturally suspected of increasing the risk
for dental caries. A few studies have agreed that probiotic lactobacilli have the
potential to enhance the cariogenicity of S. mutans and to cause subsequent tooth
mineral loss [Matsumoto et al., 2005; Pham et al., 2009; Schwendicke et al., 2014].
However, Pham et al. in 2011 have indicated that probiotic lactobacilli are not
responsible for any increase in cariogenic potential. In addition, they were even
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able to reduce caries development plus reduce the risk for early childhood caries
development [Nase et al., 2001; Stecksen-Blicks et al., 2009; Petersson et al., 2011;
Stensson et al., 2014; Hedayati-Hajikand et al., 2015; Rodriguez et al., 2016]. The
controversial results here discussed require further studies to reassure the public
and professionals as to the safety of probiotic use in the oral cavity.
2.4.6 Delivery formats
In order to meet the differing needs of customers, probiotics on the commercial
market are designed to be delivered by various vehicles and in various formats such
as fermented milk, yogurt, cheese, ice-cream, meat products, fruit and vegetable
juices, oats and cereals, and in other manners, with the help of drying techniques
[Flach et al., 2017].
Only a portion of these formats is suitable for probiotics targeting oral health,
because only a few seconds are necessary for a bite of food or a swallowed drink to
pass through the oral cavity. Probiotics need sufficient time to attach to oral
surfaces and to interact with local microorganisms, in order to exert their direct
beneficial effects.
Studies in Tables 1-3 have shown that probiotics in milk, juice, yogurt, ice-cream,
cheese, drop, (chewing) tablet, lozenge, sachet, capsule, toothpaste, and
mouthwash all have provided positive effects against caries, periodontal diseases,
or yeast infections. However, very few studies have examined whether factoring in
the type of carrying format will measurably and clinically significantly influence the
beneficial effects of probiotics on oral health.
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3 AIMS OF THE STUDY
The general aim of this thesis was to explore how probiotic lactobacilli and oral
pathogens grow in biofilms and to evaluate their mutual interactions under various
conditions.
The study hypotheses were that probiotic lactobacilli are able to integrate into oral
biofilms and affect their species composition, that probiotics interact with pathogens
and thus affect the biofilms’ pathogenic potential, and that the interactions between
probiotics and oral pathogens change after treatment of the biofilms with
commercially available mouthwashes.
The specific aims were
1. To evaluate the inhibitory activity of probiotic lactobacilli against Candida.
2. To evaluate the potential risk from lactobacilli regarding dental hard tissues
in terms of pH alterations in the growth environment.
3. To assess the growth of oral pathogens in biofilms in the presence of
Lactobacillus rhamnosus GG (LGG).
4. To assess the growth of LGG in broth and biofilms supplied with various
carbohydrate sources in the presence of opportunistic pathogens.
5. To study mouthwash effects on probiotic LGG-integrated biofilms.
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4 MATERIALS AND METHODS
4.1 Materials
4.1.1 Probiotic lactobacilli
The study included six commercial probiotic lactobacilli (Table 4). These strains
were stored as frozen stock in 10% skim milk at -80 °C. For each experiment, the
strains were subcultured twice on de Man, Rogosa, and Sharpe (MRS) agar plates at
37 °C in 5% CO2 for 24 h, and then the pure colonies were inoculated into MRS
broth and cultivated for 16-17 h, and the cell numbers were counted. Before each
test, the cells in broth were verified by Gram staining.
Table 4. Commercially available probiotic lactobacilli used in Studies I-IV.
Strains Abbreviation Source Used in study
Lactobacillus rhamnosus GG LGG
ATCC1 53103,
Valio Ltd.,
Helsinki, Finland
I, II, III, IV
Lactobacillus bulgaricus LB 86  LB 86
Laboratory
collection, LB
Lactis, Bulgaria
I
Lactobacillus bulgaricus LB LACT LB LACT
Laboratory
collection, LB
Lactis, Bulgaria
I
Lactobacillus brevis CD2 CD2
Inersan, CD
Investments srl.
Roma, Italy
I
Lactobacillus casei Shirota Shirota Yakult, Tokyo,Japan I
Lactobacillus reuteri SD2112 SD2112 ATCC 55730 I
1 ATCC: American Type Culture Collection.
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4.1.2 Oral pathogens and opportunistic pathogens.
Table 5. Oral pathogens and opportunistic pathogens used in Studies I-IV.
Strains Source Medium Air Time Study
Related to tooth decay
Streptococcus
mutans ATCC 27351 ATCC BHI
1 5% CO2 24 h II, III, IV
Streptococcus
sanguinis ATCC
10556
ATCC BHI 5% CO2 24 h II, III, IV
Related to periodontitis
Aggregatibacter
actinomycetemcomit
ans ATCC 43718
ATCC BHI 5% CO2 24 h II, III, IV
Fusobacterium
nucleatum ATCC
25586
ATCC Brucella Anaerobic2 48 h II, III, IV
Related to yeast infection
Candida albicans
ATCC 10231 ATCC Sabouraud Air O/N
3 I, II, III, IV
Candida glabrata
ATCC 90030 ATCC Sabouraud Air O/N I
Candida krusei ATCC
6258 ATCC Sabouraud Air O/N I
1 BHI: brain heart infusion; 2 anaerobic: mixture of 0.2% O2, 5% CO2, 9.9% H2, 84.9%
N2; 3 O/N: overnight.
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4.1.3 Mouthwashes
Table 6. Commercial mouthwashes used in Study IV.
(To appear in the Open Access journal Dentistry Journal)
Trade name Main active component Manufacturer
Corsodyl® 0.2% (or 2 mg/mL) chlorhexidine
gluconate
GlaxoSmithKline,
UK
Listerine® Total
Care
Essential oils: eucalyptol 0.092%, methyl
salicylate 0.060%, thymol 0.064% and
menthol 0.042%
Johnson &
Johnson, UK
Meridol® Amine fluoride and stannous fluoride
(250 ppm F-)
GABA, Switzerland
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4.2 Study designs
The five aims of this thesis project were studied in the four original studies. Their
interconnections are illustrated in Figure 1.
Figure 1. Overview of aims, measurements, microbes, and biofilms in Studies I-IV.
4.2.1 Inhibitory activity of probiotic lactobacilli against Candida (I)
We evaluated the inhibitory activity of six commercial Lactobacillus probiotic strains
against three opportunistic oral Candida strains. From this study, the Lactobacillus
species showing the strongest inhibitory activity and the Candida species with the
highest susceptibility, LGG and C. albicans, were the strains selected for Studies II-
IV.
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4.2.2 Potential risk to dental hard tissues of lactobacilli (I-III)
The pH alterations in the growth environment served in evaluation of the potential
risk to dental hard tissue.
Lactobacilli growing as planktonic cells (I)
The acid-producing abilities of lactobacilli were evaluated by measurement of the
pH alteration of MRS broth containing a sole carbohydrate, namely either fructose,
glucose, lactose, sorbitol, or sucrose, when inoculated with lactobacilli.
Lactobacilli growing as biofilm cells (II and III)
The acid-producing abilities of LGG were also evaluated in biofilms. First, we
cultivated the biofilms of the groups Sm+LGG, Ss+LGG, Ca+LGG, 4SP+LGG, and
5SP+LGG in normal biofilm medium (with glucose as the carbohydrate source). The
pH values of the spent media were measured at 16.5 h, 40.5 h, and 64.5 h. The
biofilm groups without LGG served as control groups. The biofilm group
composition is in Table 7.
Secondly, we cultivated the biofilms of group 5SP+LGG in biofilm medium with a
sole carbohydrate, namely either fructose, glucose, lactose, sorbitol, or sucrose.
The pH values of the spent media were measured at 16.5h, 40.5 h, and 64.5 h.  The
biofilm medium without carbohydrate, but with water instead served as the
negative control. The biofilm groups without LGG (5SP) served as control groups.
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Table 7. Strain composition of the biofilm groups, respective agars, and cultural
conditions to detect viable cells from biofilms.
Group Strain composition Biofilm culture Agars and culture
LGG LGG
64.5 h, 37 °C,
anaerobic condition,
saliva-coated
hydroxyapatite discs,
media added and
refreshed at 0, 16.5,
and 40.5 h.
72 h, 37 °C,
LGG: MRS in 5%
CO2,
Ca: Sabouraud in
air,
Sm, Ss, Aa, Fn: BHI
in anaerobic
condition.
Ca C. albicans
Sm S. mutans
Ss S. sanguinis
Aa A. actinomycetemcomitans
Fn F. nucleatum
LGG+Ca LGG, C. albicans
LGG+Sm LGG, S. mutans
LGG+Ss LGG, S. sanguinis
4SP S. sanguinis,
A. actinomycetemcomitans,
C. albicans, F. nucleatum
4SP+LGG S. sanguinis,
A. actinomycetemcomitans,
C. albicans, F. nucleatum, LGG
5SP S. sanguinis,
A. actinomycetemcomitans,
C. albicans, F. nucleatum,
S. mutans
5SP+LGG S. sanguinis,
A. actinomycetemcomitans,
C. albicans, F. nucleatum,
S. mutans, LGG
4.2.3 Growth of pathogens in biofilms with probiotic LGG (II and III)
We cultivated the 16.5-h and 64.5-h biofilms of groups Sm+LGG, Ss+LGG, Ca+LGG,
4SP+LGG, and 5SP+LGG, and counted viable cell numbers of S. mutans, S. sanguinis,
and C. albicans in each. The biofilms of groups Sm, Ss, Ca, 4SP, and 5SP served as
control groups (Table 7).
The adhesion ratio and growth ratio of each strain we calculated by the equations
in Table 8. The biofilms we stained with the LIVE/DEAD® kit or fluorescence in situ
hybridization (FISH), and scanned with confocal laser scanning microscopy (CLSM)
for biofilm structural analysis.
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4.2.4 Growth of LGG in broth and biofilms (I-III)
Growth in broth with various carbohydrates (I)
The growth of probiotic LGG we investigated in both MRS broth medium and in
biofilm medium with one sole carbohydrate, namely either fructose, glucose,
lactose, sorbitol, or sucrose. Measurement of the optical density of each at 492 nm
indicated growth status. The negative control was water.
Growth in biofilms with various species and with different carbohydrates
Growth of LGG in biofilms with various species compositions (II)
In 16.5-h and 64.5-h biofilms, we counted the viable cell numbers of LGG of groups
Sm+LGG, Ss+LGG, Ca+LGG, 4SP+LGG, and 5SP+LGG. Group LGG served as the
control. We also stained the biofilms with the LIVE/DEAD® kit and scanned them
with CLSM for biofilm structural analysis.
Growth of LGG in biofilms with various carbohydrates (III)
In 64.5-h biofilms of group 5SP+LGG cultivated with one sole carbohydrate, namely
either fructose, glucose, lactose, sorbitol, or sucrose, the viable cell number of LGG
was counted for each. Water instead of carbohydrate served as the negative
control. The adhesion ratio and growth ratio were calculated, and the biofilms were
stained with FISH and scanned with CLSM for biofilm structural analysis.
4.2.5 Mouthwash effects on LGG-integrated biofilms (IV)
Figure 2 presents the three experimental designs of IV.
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Figure 2. Design of Study IV. 5 species: a mixture of cell suspensions of S. mutans, S.
sanguinis, A. actinomycetemcomitans, F. nucleatum, and C. albicans; LGG + 5
species: a mixture of cell suspensions of these five species and probiotic LGG (L.
rhamnosus GG); triangle-M: one-minute mouthwash exposure; CFU: plate count to
obtain colony-forming units; CLSM: biofilm structure analysis with confocal laser
scanning microscopy. (To appear in the Open Access journal Dentistry Journal)
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Pathogen responses to the mouthwash rinsing
Sensitivity of pathogens in LGG-integrated biofilms (Experiment 2)
The 16.5-h and 64.5-h biofilms of groups 5SP and 5SP+LGG underwent exposure to
mouthwashes containing chlorhexidine gluconate, essential oils, and amine
fluoride/stannous fluoride, each for one minute. Physiological saline served as the
negative control. The viable cells of streptococci and Candida were counted and the
relative survival rates calculated by the equation: relative survival rate = 100%×(CFU
exposed to mouthwash)/(CFU exposed to saline). We then compared the relative
survival rate of streptococci and Candida in biofilms with and without LGG (groups
5SP and 5SP+LGG). These biofilms we stained with the LIVE/DEAD® kit and scanned
with CLSM for biofilm structural analysis.
Recovery of pathogens in LGG-integrated biofilms (Experiment 3)
The 16.5-h biofilms of groups 5SP and 5SP+LGG we treated with mouthwashes for
one minute. We then counted the viable cells of streptococci and Candida
immediately and after another 2-day cultivation. The recovery rates of streptococci
and Candida during those 2 days we calculated by the equation:  recovery
ratesaline/Corsodyl®/Listerine®/Meridol® = (ln (CFU64.5) – ln (CFU16.5))/48 h, where CFU64.5 was
the viable cell number recorded after 2-day cultivation, CFU16.5 was recorded
immediately after the mouthwash treatment. The biofilms we stained with the
LIVE/DEAD® kit and scanned with CLSM for biofilm structural analysis.
LGG responses to mouthwash rinsing (IV)
Sensitivity of LGG in the biofilms (Experiment 1)
The 16.5-h and 64.5-h biofilms of group 5SP+LGG were treated with mouthwashes.
The viable cell numbers of LGG were plate counted and the relative survival rates
calculated. The relative survival rate of LGG we then compared with that of
streptococci and Candida. The biofilms we stained with the LIVE/DEAD® kit and
scanned with CLSM for biofilm structural analysis.
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Recovery of LGG in the biofilms (Experiment 3)
The 16.5-h biofilms of group 5SP+LGG we treated with mouthwashes. We counted
the viable cell numbers of LGG immediately and then after another 2-day
cultivation, with recovery rate calculated. The biofilms we stained with the
LIVE/DEAD® kit and scanned with CLSM for biofilm structural analysis.
4.3 Experimental methods
4.3.1 Agar-overlay inhibitory assay (I)
The agar-overlay method originally described by Kékessy and Piguet [1970] was our
choice to determine inhibitory activity. Lactobacillus cell suspension (2 μL) of
lactobacilli we inoculated on a bottom-MRS agar containing one of the following
carbohydrates: fructose, glucose, lactose, sorbitol, or sucrose. The pH of the
bottom-MRS agar was adjusted to 5.5, 6.4, or 7.2. After cultivation of the
lactobacilli anaerobically for 24 h at 37 °C, a soft Sabouraud agar with a cell
suspension of Candida was poured over the bottom-MRS agar. After 24-h
cultivation, the diameters of lactobacilli colonies and inhibition halo zones were
measured and the effective inhibition ratio (equation appears in Table 8)
calculated. Ratio scores below 0.5 are defined as slight inhibitory activity, between
0.5 and 1.5 as intermediate, and above 1.5 as strong.
4.3.2 Biofilm model (II-IV)
For the biofilm study, the model was adapted from Guggenheim et al. [2001] (the
Zurich biofilm model) and Lemos et al. [2010]. In brief, each saliva-coated
hydroxyapatite (HA) disc was placed in a vertical position in one well of a 24-well
polystyrene cell culture plate with a single inoculation of pooled bacteria or yeast
suspension or both at the very beginning. The microorganism actively adhered to
the salivary pellicle and formed the biofilms. The biofilms we allowed to grow for
16.5 h or 64.5 h at 37 °C in anaerobic conditions. The biofilm medium, originally
described by Lemos et al. [2010], was added at baseline (0 h). In biofilms grown for
38
64.5 h, the medium was refreshed at 16.5 h and 40.5 h by transferring the HA discs
to new wells.
4.3.3 Plate counting (II-IV)
The viable cell number of microbial strains from biofilms were examined by plate
counting. Biofilms on saliva-coated HA discs were washed down and sonicated into
cell suspension. Serial dilutions of the suspension we cultivated on MRS, BHI,
Brucella, or Sabouraud agars. For the agars and cultural conditions, see Table 7.
Colony-forming units (CFU) of microbial strains were counted, and the numbers
indicate their viable cell numbers in the biofilms.
In relation to the CFU, the adhesion ratio, growth ratio, relative survival rate, and
recovery rate were calculated for each study. The equations are given in Table 8.
Table 8. Equations utilized in this project.
Ratio Equation Note Study
Effective
inhibition
ratio (EIR)
EIR = (ID - CD)/CD
ID, diameter of inhibition halo;
CD, diameter of Lactobacillus
colony.
I
Adhesion
ratio (AR)
AR = CFU16.5/(ICC X ICV)
ICC, inoculated cell
concentration; ICV, inoculated
cell volume.
II
Growth
ratio (GR)
GR = CFU64.5/average of
CFU16.5
CFU16.5, CFU acquired from 16.5-
h bioflms; CFU64.5, CFU acquired
from 64.5-h biofilms.
II
Relative
survival
rate (RSR)
RSR = 100% X CFUexposed to
mouthwash /CFUexposed to saline
CFUexposed to mouthwash/saline, CFU
acquired from biofilms treated
with mouthwash/saline.
IV
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Ratio Equation Note Study
Recovery
rate (RR)
RR = (ln (CFU64.5) - ln
(CFU16.5)) /(64.5 - 16.5)
CFU16.5, CFU acquired from 16.5-
h biofilms treated with
mouthwashes; CFU64.5, CFU
acquired from 64.5-h biofilms
treated with mouthwash at 16.5
h.
IV
4.3.4 Live/dead cell staining (II and IV)
Biofilms cultivated on saliva-coated HA discs were stained with the LIVE/DEAD®
BacLightTM Bacterial Viability Kit (catalog number L7007, Molecular ProbesTM, Life
TechnologiesTM, Eugene, OR, USA) at room temperature. Syto 9 stained live cells,
and propidium iodide dead cells.
4.3.5 Fluorescence in situ hybridization (III)
FISH served to analyze the biofilm structure. Biofilms were fixed with 4%
paraformaldehyde, permeabilized, prehybridized in hybridization buffer, hybridized
with fluorescently labeled oliogonucleotides (Table 9), washed, and stained with
Hoechst 33342 (Thermo ScientificTM, Rockford, IL, USA). The samples were
embedded in Mowiol overnight at room temperature.
Table 9. Description and specificity of oligonucleotide probes in this study.
Probe Label Target
bacteria
Target sequence (5´-3´) Reference
Lcas467 Cy3 LGG CCGTCACGCCGACAACAG [Ardita et al., 2014]
MUT590 Cy5 S. mutans ACTCCAGACTTTCCTGAC [Quevedo et al.,
2011]
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4.3.6 Confocal laser scanning microscopy (II-IV)
By CLSM (Leica SP8, Leica Microsystems Gmbh, Wetzlar, Germany) we scanned the
biofilm samples treated with LIVE/DEAD® kit and the FISH method. The images
were obtained with a ×60 glycerol-immersion objective or a ×40 water-immersion
objective. Each biofilm was scanned in randomly selected areas as a series of
vertical optical sections; each section was 0.50 µm thick. The digital images were
processed with software ImageJ or Fiji [Schneider et al., 2012].
4.4 Statistical analyses
All experiments were carried out in triplicate, each experiment with two parallels. A
significant difference was deemed as *p < 0.05, **p < 0.01, ***p < 0.001. Non-
parametric Mann-Whitney U tests served for data in Figures 4-6 and Tables 11-12.
One-way ANOVA and Duncan’s tests were applied for data in Table 13.
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5 Results
5.1 Inhibitory activity of probiotic lactobacilli against Candida (I)
The most pronounced inhibitory activity of the lactobacilli occurred in the presence
of glucose and at pH 5.5. The EIRs of lactobacilli against Candida are in Table 10.
LGG, Shirota, SD2112, and CD2 were able to inhibit C. albicans. LGG produced a
slight inhibitory effect on C. glabrata, but none of the lactobacilli had any effect on
C. krusei. Because the highest EIR against C. albicans was detected with LGG. LGG
and C. albicans were therefore selected for further testing in the following series of
studies.
Table 10. The effective inhibition ratio of Lactobacillus to Candida, the bottom MRS
agar with glucose, pH 5.5.
C. albicans C. glabrata C. krusei
LGG Intermediate1 Slight N
Shirota Intermediate N N
SD2112 Slight2 N N
CD2 Slight N N
LB86 N3 N N
LB LACT N N N
1 Intermediate: intermediate inhibitory activity, 0.5 < EIR < 1.5; 2 Slight: slight inhibitory
activity, EIR < 0.5; 3 N: no inhibition.
5.2 Potential risk for dental hard tissues from lactobacilli (I-III)
5.2.1 Lactobacilli growing as planktonic cells (I)
A species-dependent change in pH was measurable. When lactobacilli were
cultured in MRS broth containing one of the carbohydrates being tested, a species-
dependent change in pH was detectable. The 24-h pH values of culture media are in
Figure 3.
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The lowest pH was for Shirota in fructose, glucose, and lactose, and for SD2112 in
sucrose, and for LGG in sorbitol. Growth of LGG reduced the pH to 3.7-3.8 in
fructose and glucose, to 4.4 in sorbitol, and to 5.4-5.5 in lactose and sucrose.
Figure 3. pH of spent media inoculated with Lactobacillus under various
carbohydrate conditions.
5.2.2 Lactobacilli growing as biofilm cells (II and III)
Growth of LGG in biofilms with different species compositions (II)
The biofilm growth led to lowering the pH of the spent culture media at all three
time points (Figure 4). The pH of groups LGG, Ca+LGG, and Ss+LGG was each all
significantly (p < 0.001) lower than the pH of groups without LGG, namely Negative
(the group inoculated with only saline), Ca, and Ss, at all three time points. The pH
of group 5SP+LGG was significantly (p < 0.05) lower than that of group 5SP at 16.5
h. The pH of group 4SP+LGG was significantly (p < 0.05) lower than that of group
4SP at 64.5 h. No significant differences appeared between the pH of groups Sm
and Sm+LGG (p > 0.05) at any time point.
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Figure 4. The pH of spent media in which biofilms grew. Negative: group inoculated
with only saline, not with cell suspension.
Growth of LGG in biofilms with different carbohydrates (III)
No significant differences appeared between the pH of groups 5SP and 5SP+LGG at
any time point with each of the carbohydrates (p > 0.05).
5.3 Growth of pathogens in biofilms with probiotic LGG (II and III)
The growth of pathogens in biofilms depended on species composition and was
affected by the presence of LGG (Table 11).
The addition of LGG led to an increased adhesion ratio of C. albicans, but this
difference fell short of significance (p = 0.057). The growth ratio of C. albicans was
significantly reduced in group Ca+LGG (105.5 ± 40.9%) compared to that in group
Ca (319.8 ± 133.4%) (p < 0.05).
The adhesion ratio of S. mutans was lower in group Sm+LGG (7.0 ± 2.2%) than in
group Sm (24.8 ± 14.9%) (p = 0.057). A statistically significant difference (p < 0.05) in
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the growth ratio of S. mutans was observable in group Sm+LGG (4490.1 ± 1338.6)
compared to that in group Sm (918.3 ± 620.1), but no similar difference occurred in
multi-species group 5SP+LGG compared to group 5SP (p > 0.05).
The adhesion ratio of S. sanguinis was higher in group Ss+LGG (1.6 ± 0.9) than in
group Ss (0.1 ± 0.1) (p < 0.05), and in group 4SP+LGG this difference approached
statistical significance (p = 0.057). The growth ratio of S. sanguinis was significantly
higher (p < 0.05) in group Ss+LGG than in group Ss, but was significantly lower (p <
0.05) in the multispecies group without S. mutans (4SP+LGG) than in 4SP. No
significant differences in adhesion ratio and growth ratio of S. sanguinis occurred in
5SP and 5SP+LGG (p > 0.05).
Table 11. Adhesion ratios and growth ratios of pathogens in biofilm groups
cultivated with and without LGG.
Strain Biofilm
group
Adhesion ratio
(%)
p value Growth ratio
(%)
p value
C. albicans Ca 0.5 ± 0.2
0.057
319.8 ± 133.4
0.029*
Ca+LGG 1.7 ± 1.4   105.5 ± 40.9↓
4SP 0.3 ± 0.3 0.200
710.5 ± 328.5
0.486
4SP+LGG 1.0 ± 0.7 463.5 ± 283.0
5SP 0.6 ± 0.3 0.686
1612.5 ± 715.6
0.486
5SP+LGG 1.5 ± 2.0 1172.8 ± 696.9
S. mutans Sm 24.8 ± 14.9
0.057
918.3 ± 620.1
0.029*
Sm+LGG 7.0 ± 2.2     4490.1 ± 1338.6↑
5SP 20.8 ± 9.6 1.000
12006.7 ± 6645.7
0.886
5SP+LGG 27.5 ± 21.6 10578.2 ± 5402.7
S. sanguinis Ss 0.1 ± 0.1
0.029*
15.3 ± 9.2
0.029*
Ss+LGG     1.6 ± 0.9↑ 58.7 ± 27.4↑
4SP 22.7 ± 7.7
0.057
1210.3 ± 498.7
0.029*
4SP+LGG 42.8 ± 7.7       189.8 ± 129.7↓
5SP 37.2 ± 28.1 1.000
358.1 ± 415.6
0.343
5SP+LGG 35.1 ± 21.7 377.6 ± 192.4
Cell adhesion ratio of each strain to saliva-coated HA discs at their adhesion stage; Viable
cells’ growth ratio for each strain in each group at their self-development stage;­ / :¯
higher/lower than LGG-free group; Data represent means ± SDs. *p < 0.05.
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5.4 Growth of probiotic LGG in broth and biofilms (I-III)
5.4.1 LGG grown in broth medium (I and III)
The carbohydrate utilization profile of LGG in biofilm medium was similar to that in
MRS broth. LGG grew with glucose, fructose, and sorbitol but not with lactose or
sucrose. The maximum optical densities measured for biofilm culture media and
MRS broth in the presence of LGG were 0.1455 (at 490 nm) and 1.137 (at 492 nm).
5.4.2 LGG grown in biofilms
LGG grown with different strains (II)
LGG showed better growth in all dual- and multi-species biofilm groups than in
group LGG (p < 0.05), except in group Ss+LGG which fell short of significance (p =
0.057) (Table 12). The adhesion ratio of LGG in group 4SP+LGG was significantly
higher than that in group LGG (p < 0.05).
Table 12. The adhesion ratio and growth ratio of LGG cultivated with different
species.
Biofilm group Adhesion ratio of
LGG
p value Growth ratio of LGG p value
LGG 10.5 ± 6.2 -          6.7 ± 3.8 -
Ca+LGG 12.0 ± 5.5 1.000 944.6 ± 579.5↑ 0.029*
Sm+LGG 13.2 ± 2.1 0.343 32.3 ± 17.6↑ 0.029*
Ss+LGG 11.8 ± 9.7 1.000       16.5 ± 7.7 0.057
4SP+LGG    23.4 ± 4.4↑ 0.029* 566.8 ± 217.2↑ 0.029*
5SP+LGG 7.0 ± 3.3 0.686 215.3 ± 108.5↑ 0.029*
Cell adhesion ratio of LGG to saliva-coated HA discs at adhesion stage; Viable cells growth
ratio of each strain in each group at their self-development stage;­ / :¯ higher/lower than
Group LGG; Data represent means ± SDs, *p < 0.05.
Growth of LGG with various carbohydrates in 5SP+LGG (III)
The growth of LGG in biofilm group 5SP+LGG varied, depending upon the presence
of various carbohydrates (Table 13). In these multi-species biofilms, LGG grew
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significantly better in the presence of fructose, glucose, lactose, and sucrose when
compared to the presence of sorbitol (p < 0.05). When no carbohydrate was added
to the medium, LGG was still able to produce biofilms.
Table 13. Viable cell number of LGG from 64.5-h biofilms group 5SP+LGG cultivated
with a sole carbohydrate.
Carbohydrate group Viable cells of LGG (Log10 CFU/disc)
Negative 3.474 ± 0.337 a
Sorbitol 5.166 ± 0.178 b
Fructose 5.966 ± 0.262 c
Glucose 6.296 ± 0.308 c
Lactose 5.860 ± 0.206 c
Sucrose 6.335 ± 0.174 c
Negative: carbohydrate free; Different small letters represent a significant difference, p <
0.05.
5.5 Mouthwash effects on pathogens in biofilms with probiotic LGG
(IV)
5.5.1 Relative survival rates of streptococci and Candida
The relative survival rates of S. mutans, S. sanguinis, and C. albicans in 1- and 3-day
biofilm group 5SP+LGG did not significantly differ from that in group 5SP (Figure 5).
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5.5.2 Recovery rate of streptococci and Candida
The recovery rates of S. mutans, S. sanguinis, and C. albicans in group 5SP+LGG
after mouthwash rinsing did not differ significantly from those in group 5SP (Figure
6).
Figure 6. Recovery rates of S. mutans, S. sanguinis, and C. albicans in LGG-free (-LGG) and
LGG-integrated (+LGG) biofilms after mouthwash rinsing. Values as diamonds. PS,
physiological saline. No significant difference observable (p > 0.05). (To appear in the Open
Access journal Dentistry Journal)
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6 Discussion
6.1 Inhibitory activity of probiotic lactobacilli against Candida (I)
To evaluate the inhibitory activity of lactobacilli against C. albicans and non-albicans
Candida, the agar-overlay assay was employed with various pH and single
carbohydrate in the agar layer at the bottom. Four species of the lactobacilli
showed inhibitory effects: effects occurring against C. albicans; a slight LGG
inhibition of C. glabrata; but no lactobacilli species inhibition of C. krusei. Under the
conditions of this study, the Lactobacillus strains showed a stronger inhibitory
effect against C. albicans than against non-albicans Candida.
Jorgensen et al. [2017] provided similar findings that L. reuteri showed better
inhibitory activities against C. albicans than against C. krusei, and this applied both
to clinical isolates and to reference Candida strains. The non-albicans Candida
appeared in its host after administration of antifungal drugs, which makes it
unsurprising to find stronger survivability of non-albicans Candida. Nevertheless, it
may appear that non-albicans Candida is not susceptible to lactobacilli. Bulgasem et
al. [2016] isolated new potential lactic acid bacteria from honey that shows an even
stronger inhibition activity against C. krusei than against C. albicans. Furthermore,
in a spot overlay assay, in a plate-based microtiter assay, and in one biofilm model,
vulvovaginal-candidiasis-causing C. glabrata has been inhibited by L. rhamnosus GR-
1 and L. reuteri RC-14 [Chew et al., 2015a, b]. The reasons why the inhibition of
probiotic lactobacilli showed different effects on different species of Candida are
still unknown.
Data from some clinical trials have demonstrated certain inhibitory activities of
probiotic lactobacilli, Bifidobacterium, Propionibacterium, and Streptococcus
against Candida, but the intake of probiotic L. reuteri or S. salivarius has shown no
effect on the species profile of Candida in caries-active children or in participants
with systemic oral lichen planus [Burton et al., 2013; Keller and Kragelund, 2018].
Mendonca et al. [2012] observed a minor reduction in numbers of non-albicans
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species in the mouths of elderly individuals after their consumption of a probiotic
mixture of L. casei and B. breve.
6.2 Potential risk of lactobacilli for dental hard tissues (I-III)
The second aim was to evaluate the potential risk that lactobacilli may impose on
dental hard tissue by their lowering the oral environment’s pH. We added various
sugars to the culture medium and then compared the pH of spent culture media
when lactobacilli were grown in MRS broth or in a single- or multi-species biofilm
model.
The acid-producing ability of lactobacilli was confirmed, indicating that the pH
alterations by the addition of LGG were more pronounced in mono- and dual-
species biofilm groups, but neither in multi-species biofilms nor in those cultured
with S. mutans. Madhwani and McBain [2011] reported similar results, finding that
the exposure of L. reuteri on salivary biofilm microcosms in an HA disc model and
mature continuous culture plaques with constant-depth film fermenters caused no
significant pH decreases. Pham et al. [2011] also reported that LGG did not affect
the pH when cultured with S. mutans in dual-species biofilms or in saliva-derived
microcosms. In contrast, another in vitro dental biofilm model provided support for
the finding that LGG co-cultured with S. mutans for 10 days led to significant
mineral losses in dental tissue in comparison to results for tissue exposed to
biofilms containing S. mutans or LGG alone [Schwendicke et al., 2014].
This discrepancy between study results may be attributable to differences in culture
media or in the biofilm species. Schwendicke et al. [2014] cultivated their biofilms
with BHI containing 2% sucrose, a nutrient-rich medium. This medium enabled both
LGG and S. mutans to grow well with less competition; along with their growth,
acids in the broth and the mineral loss increased. Some studies [Madhwani and
McBain, 2011; Pham et al., 2011], however, utilizing artificial saliva medium, which
is similar to the nutritional environment of human saliva, showed no pH decrease in
the culture, which is consistent with the findings of this thesis. In such nutrition-
depleted media, the biofilm strains may need to compete with the surrounding
51
species for nutrients, and the final pH depends on the energy sources available.
Second, the biofilm species also influenced the final pH. In an environment with
limited nutrition, the microorganisms cultured with other species were more liable
to make full use of nutrients. They proliferated better, and they created more types
of acids or metabolites than were evident in mono- and dual-species groups.
Consequently, the acids or metabolites could be digested by the synergistic effect in
a microbial environment [Schink, 2002].
To conclude, in this in vitro study, the addition of LGG did not lead to increased
potential risk for dental hard tissues in a multi-species group with the growth media
that we tested.
6.3 Growth of pathogens in biofilms with probiotic LGG (II and III)
In our investigation of the inhibition by LGG of oral pathogenic strains in dual- and
multi-species biofilm groups, LGG reduced the growth of C. albicans in all biofilm
groups, reduced the adhesion ratio of S. mutans in the dual-species biofilm group,
and reduced the growth ratio of S. sanguinis in the biofilm group 4SP+LGG.
Our results agree with previous in vitro reports that Lactobacillus strains inhibit the
biofilm development of C. albicans [Song and Lee, 2017; Rossoni et al., 2018a].
Moreover, the short-term administration of single and multi-species probiotic
lactobacilli have lowered Candida counts in the elderly and in individuals treated
with Candida-associated stomatitis [Hatakka et al., 2007; Li et al., 2014; Ishikawa et
al., 2015; Kraft-Bodi et al., 2015]. The underlying mechanisms of inhibitory activity
are not yet fully understood, however. Basson [2000] noted that in a chemostat
with mixed microbial species under both glucose-limited and -excess conditions, L.
casei consumed glucose faster than did C. albicans. Recent studies [James et al.,
2016; Ribeiro et al., 2017; Rossoni et al., 2018a; Tan et al., 2018] reported that the
supernatant of lactobacilli showed similar effects as did lactobacilli cells in reducing
the biofilm formation of C. albicans and non-albicans Candida, and it
downregulated the expression of C. albicans genes (ALS3, HWP1, EFG1, and CPH1)
involved in the biofilm formation.
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These findings confirmed the beneficial effects of the extracellular metabolites of
lactobacilli. Probiotic lactobacilli have also shown the ability to reduce the virulence
of Candida, including reduction in adhesion, invasion, and hyphal extension
[Matsubara et al., 2016; Mailander-Sanchez et al., 2017]. Mailander-Sanchez et al.
[2017] also further demonstrated, first, that LGG did not directly affect the viability
of C. albicans; second, glucose depletion dramatically altered the composition of
the cell membranes and caused reorganization of organelles; third, the synergy
effects of glucose depletion and reduced adhesion induced a reduction in C.
albicans-caused epithelial damage. However, in our study, LGG caused a slight
increase in the adhesion ratio of C. albicans in all biofilm groups, possibly because
of the cell concentration of LGG, which was not high enough at the adhesion stage
to produce a functional concentration of extracellular metabolites able to hinder
the adhesion of C. albicans. Another mechanism may be via some extracellular
metabolite utilized by C. albicans that improved the C. albicans adhesion ratio.
A reduction in the S. mutans adhesion ratio in the present experimental group
Sm+LGG emerged to a greater extent than in the group Sm. Other studies [Chung et
al., 2004; Tahmourespour et al., 2011; Lee and Kim, 2014; Savabi et al., 2014; Wu et
al., 2015; Ciandrini et al., 2016; Wasfi et al., 2018] have shown that the addition of
probiotic Lactobacillus, its cell-free supernatant, and its biosurfactants
downregulates the expression of genes encoding glucosyltransferases (gtfB and
gtfC) and fructosyltransferase (ftf). These are associated with biofilm formation by
S. mutans, and therefore inhibit the adhesion of S. mutans.
Interestingly, the growth ratio of S. mutans was more significantly enhanced in our
experimental group Sm+LGG than in the group Sm. This result is consistent with
findings [Wen et al., 2010] that biofilm formation by S. mutans was modestly
increased when it was co-cultured with L. casei in dual-species biofilms. This result
may be related to the metabolites of lactobacilli, which can be consumed also by S.
mutans. However, in our study, the reduced adhesion ability and increased growth
of S. mutans coinciding with the addition of LGG to the dual-species group did not
appear in the multi-species group. The reason may be that in the multi-species
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ecosystem, various bacterial and yeast cells were interacting with each other, the
effect of LGG was diluted by effects of the other microorganisms, or the other
stains each had a stronger influence than that of LGG. Similar results also appear
with S. sanguinis, whose growth LGG inhibited in the experimental group 4SP+LGG
compared with its growth in group 4SP, but these effects disappeared in group
5SP+LGG when compared with the effects in group 5SP. S. sangunis may thus be
influenced more by S. mutans than by LGG. The underlying mechanisms still need
further exploration, however.
To conclude, LGG inhibited biofilm formation by C. albicans in all experimental
settings, but the effects of LGG on S. mutans and on S. sanguinis varied depending
on the group composition.
6.4 Growth of probiotic LGG in broth and biofilms (I-III)
Our results showed that LGG growth was promoted in all the dual- and multi-
species groups tested and that the highest growth ratio occurred in the
experimental group Ca+LGG.
LGG growing alone in the culture did not show good biofilm-forming ability, but its
growth was greater in the presence of S. mutans, S. sanguinis, C. albicans and in the
multi-species community. These findings agree with previous ones [Filoche et al.,
2004; Pham et al., 2009; Wen et al., 2010; Wen et al., 2017]. In dual-species
biofilms, S. mutans has led to increased biofilm growth of L. casei, L. rhamnosus, L.
plantarum, and also L. gasseri, but not the growth of L. fermentum [Filoche et al.,
2004; Wen et al., 2010; Wen et al., 2017]. L. salivarius W24 has also shown better
biofilm growth in a saliva-derived microbial community in vitro [Pham et al., 2009].
One possible reason may be that S. mutans and other microorganisms adhered to
the salivary pellicle and provided more binding sites to the later colonizer, LGG. The
other possibility may have been secondary metabolites generated by S. mutans and
other microorganisms that could stimulate the growth of LGG.
Our study further indicates that the viable cell population of LGG in biofilm
formation was substantially enhanced in the presence of C. albicans cells alone or
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with its cell-free culture supernatant, or with them both. This result is in contrast to
an observation by Liu and Tsao [2009], that yeast addition did not affect the growth
of L. rhamnosus DR20 in fermented milk. They also showed that C. kefyr NCYC 143,
C. krusei MUY-14, and other yeasts improved the survival of L. rhamnosus DR20 in
fermented milk and yoghurt. Such a discrepancy may again be attributable to the
culture media. The latter study used whole milk as a medium, whereas for our
study we chose a nutrient-depleted medium. The metabolites of Candida may
therefore also benefit the growth of Lactobacillus. Nevertheless, numerous studies
and patents have provided evidence of the enhanced stabilization of lactobacilli
with the aid of yeast. For instance, the addition of dried non-viable yeasts has
served to maintain the stability of dried viable lactic acid bacteria such as L.
acidophilus [Hsia, 2001].
In summary, the present results show enhanced biofilm growth of LGG when
streptococci, Candida, and multispecies were present.
6.5 Mouthwash effects on LGG-integrated biofilms (IV)
Evaluation of mouthwashes in regard to the sensitivity to and recovery of
microorganisms in the multi-species biofilms showed that all the mouthwashes
clearly inhibited LGG. Its recovery was slower than that of the streptococci and
Candida. LGG showed no influence upon the response of the streptococci and
Candida to the mouthwash rinsing, however.
When treated with the mouthwashes, LGG in the biofilms died easily and recovered
slowly. Earlier studies have also indicated that Lactobacillus species is sensitive to
mouthwashes [Malhotra et al., 2011; Yousefimanesh et al., 2015; Oliveira et al.,
2017]. Some researchers have, however, also shown the opposite in vitro results
[McDermid et al., 1987; Zheng and Wang, 2011; Evans et al., 2015] and in vivo
results [Sari and Birinci, 2007; Aminabadi et al., 2011]. The reasons for these
differences are unknown, but indicate that mouthwashes and the administration of
probiotics should not take place simultaneously. The active ingredients in
mouthwashes indiscriminately killed the microorganisms, and the recovery of the
55
surviving LGG was too slow to show any further beneficial effects. Hence, a
practical suggestion for the consumer may be to take probiotics only following any
mouthwash rinse.
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7 KEY FINDINGS AND CONCLUSIONS
The present results imply that probiotics can suppress the growth of certain
pathogens under proper conditions, that they should not affect dental health
detrimentally, and that they do not interfere with the use of mouthwashes. The
main findings can be summarized as follows:
1. The capabilities of probiotic lactobacilli in inhibiting the growth of C.
albicans were strain-dependent and modified by pH and sugars. No
inhibition against C. glabrata and C. krusei occurred.
2. The probiotic LGG did not significantly reduce the pH when cultivated with
the other five species of oral pathogens in multi-species biofilm models.
None of the sugars tested changed these results.
3. The probiotic LGG led to increased growth of S. mutans and S. sanguinis
compared with their growth without LGG, but inhibited the growth of C.
albicans.  LGG had no impact on the growth of the pathogens in the multi-
species biofilms, but it reduced the growth ratio of S. sanguinis in the
absence of S. mutans.
4. Probiotic LGG in multi-species biofilms was able to survive and grew well
with lactose or sucrose as its only carbohydrate source.
5. LGG neither enhanced nor weakened the antimicrobial effects of
mouthwashes on the pathogens. The residual LGG had no effect on
pathogens’ recovery.
6. C. albicans significantly elevated the growth level of LGG in biofilms.
Based on these results, it will be interesting to further study whether the
colonization of probiotic lactobacilli remains longer in individuals with C. albicans
than in those lacking C. albicans, which finding may benefit patients with oral yeast
infections. In addition, it is essential to find a proper delivery system of probiotic
administration in the oral cavity to ensure long-lasting effects.
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